Subscribe

  • How Can We Help You?

    Global Problem Solving from Covington: Deal with Complex Problems Anywhere in the World

Unsecured Synthetic Royalties May Be Returning

Article

Law360

The recent HCRx-Oncoceutics royalty monetization, following last year's Royalty Pharma-Revolution Medicines synthetic royalty financing, signals that investors are again willing to accept unsecured synthetic royalty exposure under the right circumstances. These deals mark a notable shift in a market that had largely moved away from unsecured structures after a multiyear market freeze triggered by a 2022 Mallinckrodt bankruptcy decision.

View More

Share links:

Share links:

Related Professionals

Related Practices

Related Industries

Related Offices

Related Regions

Related Topics

Related News & Insights